Status:
COMPLETED
Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Multiple Myeloma
Eligibility:
All Genders
Phase:
NA
Brief Summary
Primary Objectives: 1. To evaluate clinical tolerance and response to curcumin alone and in combination with Bioperine in patients with multiple myeloma. 2. To compare the pharmacokinetics and pharma...
Detailed Description
Curcumin, a yellow substance extracted from the plant Curcuma longa, is commonly used as a food additive. It is a natural anti-inflammatory compound and has shown anti-tumor activity in the laboratory...
Eligibility Criteria
Inclusion
- Patients with multiple myeloma who have been previously untreated, are asymptomatic and without serious or imminent complications; or have relapsed or failed treatment with conventional therapy.
- Adequate hematologic, renal, and hepatic functions.
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
Exclusion
- Previously untreated patients with high tumor mass; symptomatic or impending fractures.
- Patients with significant cardiac disease.
- Patients with comorbid condition which renders patients at high risk of treatment complications.
- History of significant neurological or psychiatric disorders.
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00113841
Start Date
November 1 2004
End Date
August 1 2009
Last Update
November 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
U.T.M.D. Anderson Cancer Center
Houston, Texas, United States, 77030